Skip to main content

Table 1 Demographic and clinical characteristics of the CHR and healthy control groups

From: Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis

  CHR n = 162 HC n = 105   
  n (%) n (%) χ 2 p-value
Sex     
 Male 96 (59) 57 (54) 0.62 0.43
 Female 66 (41) 48 (46)
Race     
 First Nations 2 (1) 2 (2) 10.1 0.26
 Asian 9 (6) 10 (10)
 Black 35 (22) 28 (27)
 Latin America/Middle East/White 93 (57) 59 (55)
 Inter-racial 23 (14) 6 (6)
AUS/DUS cannabis use frequency     
Abstinent 112 (69) 92 (88) 17.1 0.004
 1–4 times per month 26 (16) 11 (10)
 1–4 times per week 21 (13) 2 (2)
 Almost daily 3 (2) 0 (0)
AUS/DUS cannabis use severity     
 Abstinent 116 (72) 92 (88) 11.7 0.003
 Use without impairment 37 (23) 13 (12)
 Abuse 9 (6) 0 (0)
  Mean (SD) Mean (SD) t p-value
Age (years) 19.4 (4.21) 19.5 (4.62) 0.25 0.80
Education (years) 11.8 (2.50) 12.7 (3.46) 2.32 0.02
Age at onset of cannabis use (years)a 16.1 (3.20) 16.0 (2.30) 0.25 0.81
  1. Note. CHR Clinical High Risk, HC Healthy Controls, SD Standard Deviation
  2. aInformation on age of onset of cannabis use was available for 99 CHR and 38 control participants